https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-05 / Expert Opin Biol Ther 2015;15(12):1757-712015-10-05 00:00:002021-11-15 16:52:53Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-10-01 / Anticancer Res. 2015 Oct;35(10):5401-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-10-01 / Anticancer Res. 2015 Oct;35(10):5401-62015-10-01 00:00:002015-10-01 00:00:00Sensitivity of Human Malignant Melanoma Cell Lines to Newcastle Disease Virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-27 / 2016 Feb;5(2):e1078057
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-27 / 2016 Feb;5(2):e10780572015-08-27 00:00:002015-08-27 00:00:00Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-26 / Appl. Biochem. Biotechnol. 2015 Oct;177(4):940-56
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-26 / Appl. Biochem. Biotechnol. 2015 Oct;177(4):940-562015-08-26 00:00:002019-02-15 09:22:45HN Protein of Newcastle Disease Virus Induces Apoptosis Through SAPK/JNK Pathway
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-08-24 / Technol. Cancer Res. Treat. 2016 10;15(5):NP83-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-08-24 / Technol. Cancer Res. Treat. 2016 10;15(5):NP83-942015-08-24 00:00:002019-02-15 09:13:32Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-07-26 / Virus Res. 2015 Nov;209:56-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-07-26 / Virus Res. 2015 Nov;209:56-662015-07-26 00:00:002019-02-15 09:22:42The therapeutic effect of death: Newcastle disease virus and its antitumor potential
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-26 / Mol. Ther. 2015 Oct;23(10):1630-40
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-26 / Mol. Ther. 2015 Oct;23(10):1630-402015-06-26 00:00:002019-02-15 09:22:35Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-06-11 / Viruses 2015 Jun;7(6):2980-98
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-06-11 / Viruses 2015 Jun;7(6):2980-982015-06-11 00:00:002015-06-11 00:00:00Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-28 / Immunotherapy 2015;7(8):855-60
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-28 / Immunotherapy 2015;7(8):855-602015-05-28 00:00:002021-11-16 07:55:05Long-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-05-07 / Cell Death Dis 2015 May;6:e1758
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-05-07 / Cell Death Dis 2015 May;6:e17582015-05-07 00:00:002019-02-15 09:22:47IPS-1 differentially induces TRAIL, BCL2, BIRC3 and PRKCE in type I interferons-dependent and -independent anticancer activity
